Mylan’s generic Xalatan receives regulatory approval
PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan that reduces pressure in the eye, Mylan said Monday.
Mylan announced the approval of latanoprost ophthalmic solution in the 0.005% strength. The drug is a generic version of Xalatan, made by Pharmacia and Upjohn, now part of Pfizer.
Various versions of the drug had sales of around $711 million in 2010, according to IMS Health.
Report: Sanofi-Aventis may shorten name
NEW YORK — French drug maker Sanofi-Aventis may get a name change soon, according to a published report.
Bloomberg reported that the drug maker had scheduled a vote at its May 6 stockholders meeting to shorten the name to “Sanofi.” The article paraphrased a spokesman as saying that the current name is difficult for people in some countries to pronounce.
The Sanofi-Aventis name came into being following the 2004 acquisition of Aventis by Sanofi-Synthelabo.
Many publications, including Drug Store News, already use “Sanofi” as an abbreviated form of the company’s name.
Sanofi-Aventis completes Genzyme acquisition
PARIS — Sanofi-Aventis said it completed its exchange offer for drug maker Genzyme, which expired just before midnight April 1.
All 224,528,469 shares of Genzyme common stock were validly tendered, which is represented by 84.6% of common stock and 77% of shares on a diluted basis.
Last month, the board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer.